3-Fluoro-4-Oxopyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

N-Boc-3-fluoro-4-oxopyrrolidine is stored under argon at −20 °C in sealed fluoropolymer-lined drums. Karl Fischer titration before use must return a water content below 0.15 % to suppress hydrolytic ring-opening of the β-keto carbamate. The compound is charged as a single lot into cold-jacketed reactors; pre-drying of the solid at 30 °C under 5 mbar for 6 h is mandatory whenever ambient relative humidity exceeds 55 %. A typical downstream transformation yielding enantiomerically enriched N-protected 3-fluoropyrrolidine building blocks starts from the ketone dissolved in anhydrous dichloromethane (8–10 volumes). A primary amine (1.08 eq) is added, followed by glacial acetic acid (1.5 eq) and sodium triacetoxyborohydride (1.4 eq) portionwise at 0–5 °C. The mixture is stirred for 18 h while warming to 22 °C. Quenching with saturated NaHCO₃, extraction, and crystallization from heptane/IPA delivers the 3-fluoropyrrolidine derivative in 82–88 % isolated yield. Boc deprotection is achieved with HCl in dioxane (4 M, 3 eq) or with TFA/DCM (1:1 v/v), both requiring immediate neutralization to prevent defluorination. The free amine is used directly in peptide coupling or sulfonamide formation. Process-scale campaigns demand in-process HPLC control (C18, 210 nm) with acceptance criteria for des-fluoro impurity ≤0.10 area% and the ring-opened keto-ester impurity ≤0.15 area%. Material manufactured under ICH Q7 QAGMP provisions for registered intermediates is supplied with a Certificate of Analysis referencing Ph. Eur. 2.2.46 for chromatographic purity and USP 921 for water content. End-product molecules derived from this route include melanin-concentrating hormone receptor antagonists, orexin receptor modulators, and a series of fluorinated proline mimetics evaluated for triple-reuptake inhibition.

What Makes This Activated Ketone Suitable for Gliptin Analogue Backbone Assembly?

The 4-oxo group of N-Boc-3-fluoro-4-oxopyrrolidine functions as an electrophilic anchor for constructing the pyrrolidine-2-carbonitrile or pyrrolidine-2-amide cores found in several DPP-4 inhibitors. In a synthesis stream aligned with omarigliptin-type architecture, the ketone is dissolved in tetrahydrofuran (5 volumes) and treated with a substituted 4-aminopiperidine derivative (0.98 eq) in the presence of Ti(OiPr)₄ (2.0 eq) to form the transient titanium-imine complex. After 2 h at 50 °C, the mixture is cooled to −10 °C and sodium cyanoborohydride (1.2 eq) in methanol is added dropwise over 45 min. The reaction is aged at 20 °C for an additional 12 h. Quenching with 1 M NaOH and filtration through a Celite pad removes titanium salts. The tertiary amine intermediate is isolated in 70–78 % yield after flash chromatography. A critical process conflict arises from the competing Boc-group cleavage under the mildly acidic conditions generated during cyanoborohydride decomposition; pH must be maintained at 6.5–7.0 by periodic addition of triethylamine. Alternative routes employing STAB (sodium triacetoxyborohydride) with acetic acid at 0 °C mitigate this but reduce conversion for sterically hindered anilines, requiring a ketone:amine molar ratio of 1:1.3 to reach completion. Post-coupling, the Boc group is retained through a sequence of nitrile hydrolysis and carbamoylation, then removed with TFA at 40 °C for 2 h. The final DPP-4 inhibitor must conform to the residual solvent limits of ICH Q3C; the manufacturing site’s cleaning validation targets a carryover of the fluoro intermediate at or below 10 ppm in the next product. Reference standards for the intermediate are characterized by ¹⁹F NMR (400 MHz, CDCl₃) with a signal at δ −175.3 ppm and by single-crystal X-ray diffraction to confirm relative stereochemistry. Terminal drug substances include omarigliptin and related long-acting gliptins used in once-weekly type 2 diabetes regimens.

Synthesis of CGRP receptor antagonists for migraine prevention frequently exploits the 3-fluoro-4-oxopyrrolidine scaffold as a rigid, sp³-rich bicyclic precursor. The ketone undergoes a telescoped sequence comprising reductive amination with 3-aminoazepan-2-one derivatives, Boc removal, and spontaneous lactamisation to yield a tetrahydro-1H-pyrrolo[1,2-a]azepine core. Running the sequence in a single vessel, N-Boc-3-fluoro-4-oxopyrrolidine (1.0 eq) and the amine (1.02 eq) are combined in ethyl acetate at 25 °C. After 30 min of imine formation, sodium borohydride (1.8 eq) in ethanol is added at −5 °C and the batch is stirred for 4 h. The Boc group is then cleaved by introducing anhydrous HCl gas at 10 °C until pH 2 is reached; subsequent heating to 60 °C for 8 h closes the bicyclic ring. Process robustness suffers from epimerisation at the fluorine-bearing carbon during prolonged heating at pH < 3. To limit the trans-isomer to ≤0.5 area%, the cyclisation temperature must not exceed 55 °C and the holding time is capped at 6 h. Extraction with MTBE at pH 9 followed by crystallisation from acetone/water provides the core with a purity of 99.5 %. This intermediate undergoes subsequent sulfonamide coupling and amide formation to deliver candidates evaluated in Phase II/III trials. Regulatory starting material designation per ICH Q11 requires that all manufacturing steps up to the isolated Boc-protected ketone are covered in the Drug Master File. The specification for the intermediate includes a test for heavy metals by USP <231> with an acceptance limit of ≤20 ppm and a specific optical rotation control where applicable.

When Fluorine Substitution Modulates P2 Ligand Binding in HIV-1 Protease Inhibitors

Incorporation of a fluorine atom at the 3-position of the pyrrolidine ring transforms the electronic profile of the P2 ligand in peptidomimetic HIV protease inhibitors. N-Boc-3-fluoro-4-oxopyrrolidine is converted into the corresponding (R)-3-fluoro-4-hydroxypyrrolidine using a stereoselective ketoreductase under controlled fed-batch conditions. The whole-cell biocatalyst of Lactobacillus kefir is formulated as a lyophilised powder and resuspended in potassium phosphate buffer (100 mM, pH 7.0) prior to addition. Glucose dehydrogenase and glucose are utilised as an NADPH recycling system. The substrate is charged as a 15 wt% solution in DMSO at a rate such that the dissolved substrate concentration remains below 2 mM to avoid enzyme inhibition. Reaction at 30 °C for 24 h furnishes the (R)-alcohol with 99.2 % enantiomeric excess. After ethyl acetate extraction and distillation, the alcohol is silylated with TBSCl (1.15 eq) and imidazole in DMF, then the Boc group is cleaved with TFA to expose the pyrrolidine nitrogen. The free amine is coupled to a protease inhibitor core scaffold using HATU (1.1 eq) and DIPEA (2.5 eq) in acetonitrile. The silyl group is removed with TBAF (1 M in THF, 2.0 eq) to regenerate the hydroxyl group for subsequent sulfonamide attachment. An alternative chemically catalysed route uses (S)-CBS-oxazaborolidine (10 mol%) and BH₃·SMe₂ in THF at −25 °C; this method yields the (S)-alcohol but with lower enantioselectivity (92 % ee) after one crystallisation. The final HIV protease inhibitors exhibit picomolar binding affinities and are formulated as 100 mg tablets for combination antiretroviral therapy. Compliance with ICH M7 requires monitoring of genotoxic impurities arising from the fluorinated intermediate; a purge factor calculation demonstrates that the downstream recrystallisation and acid-base extraction steps remove the alkyl fluoride impurity to a theoretical level of less than 1.5 µg/day, well below the threshold of toxicological concern.

Emerging KRAS G12C and KRAS G12D inhibitor backbones incorporate N-Boc-3-fluoro-4-oxopyrrolidine as a structural element for filling a hydrophobic sub-pocket adjacent to the switch-II binding region. The ketone participates in a one-pot Wittig olefination–hydrogenation–Boc cleavage sequence to forge a fluorinated spiro-ether intermediate. Methyltriphenylphosphonium bromide (1.3 eq) is suspended in THF, and KOtBu (1.2 eq) is added at 0 °C; the ylide mixture is stirred for 30 min before adding the protected ketone at −10 °C. After 2 h, saturated NH₄Cl is introduced to quench, and the organic phase is concentrated. The crude methylene compound is taken up in ethanol and hydrogenated over 5 wt% Pd/C (0.5 mol%) at 1 bar H₂ for 3 h. Removal of the catalyst by filtration and concentration yields the 3-fluoro-4-methylpyrrolidine, which is deprotected with HCl/dioxane and subsequently coupled to an acrylamide warhead-bearing fragment through Buchwald–Hartwig amination. The amination uses Pd₂(dba)₃ (2 mol%) and Xantphos (4 mol%) in toluene at 80 °C, securing the target inhibitor in 65 % overall yield from the Boc-protected ketone. A process bottleneck is the sensitivity of the exocyclic alkene intermediate to fluorine elimination under basic conditions; using K₂CO₃ instead of KOtBu for the Wittig step partially mitigates this but reduces conversion. The final drug substance candidate is tested according to ASTM D4169-16 for transport simulation and is stored in alu-alu blister packs to protect against photolytic defluorination. Published data for this specific configuration remain limited to patent disclosures, and predictive in-silico modelling suggests a metabolic liability associated with N-dealkylation of the pyrrolidine ring, requiring intensive CYP450 phenotyping prior to IND filing.

Fungicidal 3-Fluoropyrrole Derivatives — Synthetic Entry via the Keto Carbamate

The 3-fluoro-4-oxopyrrolidine intermediate is diverted into agrochemical research through a Paal–Knorr-type pyrrole synthesis. Condensation with aniline derivatives substituted with a para-cyano or para-methoxy group in refluxing acetic acid (118 °C, 48 h) gives an N-aryl-3-fluoropyrrole after concurrent Boc removal and aromatisation. The reaction is driven by removal of water via a Dean–Stark trap; molecular sieves (3 Å) are pre-loaded into the trap arm to enhance efficiency. After cooling and neutralization with aqueous NaOH to pH 8, the product is extracted into ethyl acetate and purified by vacuum distillation (b.p. 125–130 °C at 0.5 mbar). Yield ranges from 55–62 %, with the major side product being the des-fluoro pyrrole arising from β-elimination during prolonged heating. Catalytic amounts of SnCl₂ (5 mol%) suppress this defluorination pathway and boost yield to 75 %. The resultant 1-aryl-3-fluoropyrrole is a key intermediate in the preparation of succinate dehydrogenase inhibitor (SDHI) fungicides and exhibits activity against Botrytis cinerea in glasshouse trials at application rates of 100–200 g a.i./ha. Formulation as a 250 g/L SC requires wet-milling with a lignin sulfonate dispersant to a particle size D₉₀ ≤ 5 µm. Crop protection guidelines mandate compliance with FAO Specification 59/TC/SC and the analytical methods of CIPAC Handbook volume L; the spent mother liquor from the pyrrole synthesis is treated with ozone to destroy trace fluorinated by-products before discharge. While the fluoro pyrrole scaffold delivers improved soil mobility due to its moderate log P of 2.1, field studies indicate a half-life of 34 days in sandy loam, requiring buffer zones near surface waters per European Directive 2009/128/EC.